Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 213-424-8 | CAS number: 947-04-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro cytogenicity / chromosome aberration study in mammalian cells
- Remarks:
- Type of genotoxicity: chromosome aberration
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 1990-11-02 - 1991-02-28
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 991
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 473 (In Vitro Mammalian Chromosome Aberration Test)
- Version / remarks:
- (1983)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.10 (Mutagenicity - In Vitro Mammalian Chromosome Aberration Test)
- GLP compliance:
- yes
- Type of assay:
- in vitro mammalian chromosome aberration test
Test material
- Reference substance name:
- Dodecane-12-lactam
- EC Number:
- 213-424-8
- EC Name:
- Dodecane-12-lactam
- Cas Number:
- 947-04-6
- Molecular formula:
- C12H23NO
- IUPAC Name:
- 1-azacyclotridecan-2-one
- Test material form:
- solid
- Details on test material:
- Dodecane-12-lactam of Atochem SA, batch no. 9611, purity determined by NMR: no impurities > 0.5 % detectable
Constituent 1
Method
- Target gene:
- not applicable
Species / strain
- Species / strain / cell type:
- lymphocytes: Human
- Details on mammalian cell type (if applicable):
- Human lymphocyte cultures from a single male donor, duplicate cultures
- Metabolic activation:
- with and without
- Metabolic activation system:
- male Sprague-Dawley rat liver post-mitochondrial fraction (S-9) from Aroclor 1254 induced animals
- Test concentrations with justification for top dose:
- 30.06; 37.58; 46.98; 58.72; 73.40; 91.75; 114.7; 143.4; 179.2; 224.0; 280.0; 350.0 mg/l
- Vehicle / solvent:
- Solvent: dimethyl sulfoxide (DMSO)
Controls
- Untreated negative controls:
- yes
- Negative solvent / vehicle controls:
- yes
- Remarks:
- solvent
- True negative controls:
- yes
- Positive controls:
- yes
- Positive control substance:
- cyclophosphamide
- methylmethanesulfonate
- Details on test system and experimental conditions:
- - No. of metaphases analyzed: 100 from each culture if possible, i.e. 200 metaphases / dose group
- Number of replicates: 2
- Application:
with S-9: 3 hours treatment + 17 or 41 h recovery period
without S-9: 20 or 44 h treatment
Chromosome aberrations were analysed in cells sampled 20 hours after the start of treatment at 3 consecutive dose levels. The highest concentrations chosen for analysis at this time, 280 and 350 ug/ml, induced approximately 61% and 46% mitotic inhibition in the absence and presence of S-9, respectively. - Evaluation criteria:
- The proportions of cells with structural aberrations excluding gaps for each treatment condition were compared with the proportion in negative controls using Fisher's exact test, p <= 0.05; binominal dispersion test demonstrated acceptable homogenity between replicate cultures; proportion of cells with strucural aberrations without gaps in negative controls fell within the normal range; at least 160 cells out of an intended 200 were analysable at each treatment level; positive control chemicals both induced clear increases in number of cells with structural aberrations; test chemical is considered to be positive if: statistically significant increases in the proportion of structurally aberrant cells without gap ocurred at one or more concentrations and the proportion of aberrant cells at such data points exceeded the normal range; increases in numbers of cells with gaps or increases in numbers of cells with structural aberrrations not exceeding the normal range or occuring only at very high or toxic concentrations were likely to be concluded as "equivocal" or "probably of no biological importance". Cells with exchange aberrations or cells with greater than one aberration were to be considered of greater biological significance
- Statistics:
- Fisher's exact test, p <= 0.05
Results and discussion
Test results
- Key result
- Species / strain:
- lymphocytes: Human
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- cytotoxicity
- Remarks:
- - With metabolic activation: 46 % mitotic inhibition at 350 mg/l - Without metabolic activation: 61 % mitotic inhibition at 280 mg/l
- Vehicle controls validity:
- valid
- Untreated negative controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- Treatment of cultures with lauryl lactam in both the absence and presence of S-9 resulted in frequencies of aberrant cells which were similar to and not significantly different from those observed in concurrent negative controls. Proportions of aberrant cells in all treated cultures fell within historical negative control ranges.
- Remarks on result:
- other: other: Human Lymphocytes
- Remarks:
- Migrated from field 'Test system'.
Any other information on results incl. tables
no further remarks
Applicant's summary and conclusion
- Conclusions:
- It is concluded that lauryl lactam was unable to induce chromosome aberrations in human lymphocytes when tested to its solubility limit in either the absence or presence of S-9.
- Executive summary:
The test item lauryl lactam was tested in an in vitro cytogenetics assay using duplicate human lymphocyte cultures from a single male donor. The highest dose level used, 350 µg/ml was close to the solubility limit of lauryl lactam in culture medium. Treatments were performed both in the absence and presence of metabolic activation by a rat liver post-mitocondrial fraction (S-9). Appropriate negative (solvent) controls and positive controls (methylmethanesulphonate; cyclophosphamide) were included in the test system. Treatment of cultures with lauryl lactam in both the absence and presence of S-9 resulted in frequencies of aberrant cells which were similar to and not significantly different from those observed in concurrent negative controls. Proportions of aberrant cells in all treated cultures fell within historical negative control ranges. It is concluded that lauryl lactam was unable to induce chromosome aberrations in human lymphocytes when tested to its solubility limit in either the absence or presence of S-9.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.